



April 13, 2020

**Re: Rejuvenate™ efficacy against SARS-CoV-2, the virus which causes COVID-19 disease**

Dear Sir or Madam,

In cases of emerging viral pathogens like SARS-CoV-2, the virus that causes COVID-19, when there is no test that can be conducted to validate the efficacy of a disinfectant, the EPA utilizes Emerging Viral Pathogen Guidance to determine the expected efficacy of a disinfectant against an emerging virus. This guidance, used previously during the 2003 SARS epidemic, mandates that for disinfectant products to be approved against an enveloped or non-enveloped virus, they must be an EPA registered Hospital or Broad-Spectrum disinfectant and have proven efficacy against two small, non-enveloped viruses, such as Poliovirus and Parvovirus. The following criteria are used to determine efficacy of a disinfectant upon activation of the Emerging Pathogen Rule:

1. The product must be a hospital or broad-spectrum disinfectant product registered with EPA.
2. For an emerging enveloped virus, the product must have acceptable efficacy data previously submitted to and reviewed by the Agency against one non-enveloped virus (e.g. Poliovirus).

The Rejuvenate™ line of disinfectants (concentrate, ready-to-use and premoistened wipes) fulfill these criteria and are included on the EPA’s List N: Disinfectants for Use Against SARS-CoV-2. Simply search by the EPA Registration Number; 74559-4 for the concentrate, 74559-1 for the ready-to-use and 74559-3 for the premoistened wipes. (<https://www.epa.gov/pesticide-registration/list-n-disinfectants-use-against-sars-cov-2>).

The Rejuvenate™ line of disinfectants can be used against SARS-CoV-2 as part of a facility’s COVID-19 infection prevention and control plan on hard, non-porous surfaces. Rejuvenate™ concentrate should be applied at a 1:64 dilution for a contact time of five minutes. Rejuvenate™ ready-to-use liquid and wipes should be applied with a one-minute contact time. Refer to the CDC website at [www.cdc.gov/outbreaks/](http://www.cdc.gov/outbreaks/) for additional information.

Should you require any further information, please do not hesitate to contact me directly at 1-800-387-7578 ext. 118 or via email at [nkenny@virox.com](mailto:nkenny@virox.com).

Best Regards,

Nicole Kenny, HBSc., Assoc Chem  
Vice President, Professional and Technical Services  
Virox Technologies Inc.

